ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AbbVie will pay Frontier Medicines $55 million up front as part of a multiyear pact in which the firms will use Frontier’s chemoproteomics technology to identify small molecules that act on E3 ligases, a family of proteins that tag other proteins for degradation. The approach is considered a way to target “undruggable” proteins. Frontier, one of C&EN’s 10 Start-Ups to Watch in 2019, launched in 2018 with technology developed by University of California, Berkeley, chemical biologist Daniel Nomura. This is its first major collaboration.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter